Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher-Schwarz H-G, Hainfellner J A, Knosp E
Department of Neurosurgery, Medical University Vienna, Vienna, Austria.
Acta Neurochir (Wien). 2004 Dec;146(12):1323-7; discussion 1327-8. doi: 10.1007/s00701-004-0390-5. Epub 2004 Oct 11.
Ki-67 antigen is used as a marker of proliferative activity that is linked to growth rate, invasiveness and prognosis of pituitary adenomas. So far the distribution of Ki-67 index within an individual adenoma has not been investigated. If Ki-67 antigen expression differs significantly within an individual pituitary adenoma, a sampling error may result when assessing small fragments of adenoma tissue. Such a potential error would diminish the value of Ki-67 as a tool for postoperative patient management considerations. The aim of the present study was to assess Ki-67 proliferation rates in different regions of pituitary adenomas and to statistically analyse these data for potential regional differences within each tumor. Ki-67 proliferation index was assessed in smear preparations of 100 specimens of 26 consecutive patients operated on for pituitary adenoma in the Department of Neurosurgery, Medical University Vienna. Depending on the size and extent of the tumor, a mean of 4 tissue samples (range 2-8) was selected intraoperatively from each adenoma from endosellar, suprasellar, parasellar, and basal sellar dural locations. Overall mean cell proliferation rate measured by Ki-67 was 1.81 +/- 0.90% (range 0.33-3.43%). Histologically invasive adenomas had significantly higher mean Ki-67 proliferation index in all samples from the same tumor than non-invasive adenomas (2.01 +/- 0.91% vs. 1.11 +/- 0.59%; P = 0.024). Multiregional sampling revealed a homogenous distribution of Ki-67 index throughout an individual adenoma with no significant differences between any two different regions on t-test. Our data confirm that location of a biopsy does not influence Ki-67 index. Therefore, Ki-67 index of a single biopsy is representative for the whole individual adenoma. Thus Ki-67 index can be considered a reliable parameter for assessment of cell proliferation rate in adenoma biopsies and may be used for postoperative patient management considerations.
Ki-67抗原用作增殖活性的标志物,其与垂体腺瘤的生长速率、侵袭性及预后相关。迄今为止,尚未对单个腺瘤内Ki-67指数的分布情况进行研究。如果在单个垂体腺瘤内Ki-67抗原表达存在显著差异,那么在评估腺瘤组织的小片段时可能会导致抽样误差。这种潜在误差会降低Ki-67作为术后患者管理考量工具的价值。本研究的目的是评估垂体腺瘤不同区域的Ki-67增殖率,并对这些数据进行统计学分析,以了解每个肿瘤内潜在的区域差异。对维也纳医科大学神经外科连续26例接受垂体腺瘤手术患者的100份标本涂片进行Ki-67增殖指数评估。根据肿瘤的大小和范围,术中从每个腺瘤的鞍内、鞍上、鞍旁和鞍底硬脑膜部位平均选取4个组织样本(范围为2 - 8个)。通过Ki-67测得的总体平均细胞增殖率为1.81±0.90%(范围为0.33 - 3.43%)。组织学上侵袭性腺瘤在同一肿瘤的所有样本中的平均Ki-67增殖指数显著高于非侵袭性腺瘤(2.01±0.91%对1.11±0.59%;P = 0.024)。多区域抽样显示,Ki-67指数在单个腺瘤内分布均匀,经t检验,任意两个不同区域之间无显著差异。我们的数据证实活检部位不影响Ki-67指数。因此,单次活检的Ki-67指数代表整个个体腺瘤。所以,Ki-67指数可被视为评估腺瘤活检中细胞增殖率的可靠参数,并可用于术后患者管理考量。